Reported 3 days ago
Adaptive Biotechnologies (ADPT) has seen a significant rise, with its stock increasing by 250% over the past year and hitting a three-year high recently. While it has garnered a consistent 'Buy' recommendation from analysts and shows promising projected revenue and earnings growth, the company struggles with profitability and high volatility. As investors weigh the potential risks, Adaptive remains a subject of mixed opinions in the market.
Source: YAHOO